P/E Ratio

The P/E ratio of 17.7x means investors are paying $17.70 for every $1 of GSK’s annual earnings — a measure of how expensive the stock is relative to its profit.

This sits well below the healthcare sector median of 24.6x, placing GSK in the 22nd percentile among sector peers, meaning roughly 78% of competitors trade at higher multiples. Trend data is not available: both the year-over-year and quarter-over-quarter changes are listed as N/A, so no direction can be inferred. Without a trend, the low P/E alone suggests the stock may be undervalued compared to peers, which could indicate a margin of safety for investors, but also may reflect weaker growth expectations. This metric supports the overall NEUTRAL verdict—while the below‑median valuation is a positive signal, the lack of trend data and the broader neutral assessment imply no strong catalyst for decisive action.

Frequently Asked Questions

Closest Sector Peers